touchENDOCRINOLOGY had the pleasure of talking with TOS President Prof Dan Bessesen (UCHealth, University of Colorado, Aurora, CO, USA) around this year’s ObesityWeek®, the key highlights and future Obesity Society activities to look forward to.
- Could you tell us a little about ObesityWeek® and its key themes for 2022? (0:21)
- What do you expect to be the highlights of the scientific programme? (2:01)
- What other activities can we look forward to from the Obesity Society in 2022? (3:41)
- What do you consider the key advances in obesity research in the last year? (5:46)
Disclosures: Dan Bessesen has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd.
Share this Video
Related Videos In Obesity
Domenica Rubino, EASD 2022: The role of semaglutide in the treatment paradigm for prediabetes
Semaglutide has clinically beneficial effects on glucose metabolism and glycaemic status in patients with obesity and prediabetes. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses her thoughts on the role of semaglutide in the treatment paradigm for prediabetes. The abstract entitled: ‘Semaglutide 2.4 mg […]
Domenica Rubino, EASD 2022: Semaglutide 2.4 mg vs liraglutide 3.0 mg on glucose metabolism – STEP 8 post-hoc analysis
The aim of the STEP 8 trial (NCT04074161) was to compare the effect and safety of semaglutide 2.4 mg once weekly compared to liraglutide 3.0 mg once daily on weight management in people with obesity. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses the […]
Uberto Pagotto, ESPE 2022: GLP-1 agonists and other emerging treatments of obesity
Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity. In this touchENDOCRINOLOGY interview, Prof. Uberto Pagotto (University of Bologna, Bologna, Italy) discusses the impact of glucagon-like peptide 1 agonists on obesity, what other emerging treatments in obesity appear promising. The future direction in obesity research is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!